Premium research materials.
Research materials only • Not for human consumption
$89.99
A triple receptor agonist studied for its effects on metabolic signalling pathways. Lyophilized, third-party assayed, and sealed in a discreet vial.
From the literature
New England Journal of Medicine · 2023
A phase 2 trial of a GIP/GLP-1/glucagon triple agonist reported substantial, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal effects most common during dose escalation.
Cell Metabolism · 2022
Preclinical work outlines how adding glucagon receptor activity to incretin agonism increases energy expenditure and hepatic lipid turnover, distinguishing triple agonists from dual-agonist pharmacology.
Summaries of published literature, provided for context only. Nothing here is medical advice, and this product is sold for laboratory research use only.
Pairs well with
Dual-agonist metabolic research.
Long-acting amylin analogue.
Body protection compound.
Copper tripeptide complex.
Retatrutide
$89.99
